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Intrapleural administration of interleukin 2 in pleural mesothelioma: a
phase I-II  study
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Chemistry, Rotterdam Cancer Institute, (Daniel den Hoed Kliniek) and University Hospital, PO Box 5201, 3008 AE Rotterdam, 
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Summary Twenty-three patients with pleural mesothelioma stage I HA were entered in a study o f con­
tinuous daily intrapleural infusion of interleukin 2 (IL-2) for 14 days, repeated every 4 weeks. IL-2 was 
administered according to a groupwise dose escalation schedule (group A, 3 x  104; group B, 3 x  10s; group C, 
3 X 106; group D, 6 x  106; group E, 18 x  106; and group F, 36 X 106 IU day"1). Each group consisted o f at 
least three patients. Intrapleural administration of IL-2 was associated with acceptable toxicity. All patients 
were treated on an outpatient basis except for the patients at dose levels E and F. Dose-limiting toxicity was 
observed at level F, 36 x IO6 IU daily, and consisted of catheter infection, fever and flu-like symptoms. 
Intrapleural IL-2 levels were high (> 2 0  000117 011“ ’) at levels E and F, while serum levels in most patients 
were not or barely detectable ( < 3 - 3 0  IU ml"1). Intrapleural IL-2 levels were up to 6000-fold higher than 
systemic levels. Intrapleural tumour necrosis factor alpha (TNF-a) levels varied greatly and did not correlate 
with IL-2 dosage. Intrapleural mononuclear cells (MNCs) displayed IL-2-induced lymphokine-activated killer 
(LAK) activity in all patients. Two patients were not evaluable for response owing to catheter-related 
problems which precluded the delivery of IL-2. Partial response (PR) occurred in 4 o f 21 evaluable patients 
(19%; 95% confidence interval 5-42% ) with a median time to progression of 12 months (range 5-37). Stable 
disease (SD) occurred in seven patients with a median time to progression of 5 months (range 2 -7). There 
were no complete responses (CRs). The median overall survival was 15.6 months (range 3.0-43). No 
relationship between the dose o f  IL-2 and response rate was observed. We conclude that IL-2 given 
intrapleurally is accompanied with acceptable toxicity and has anti-tumour activity against mesothelioma. In 
view of the refractory nature o f  the disease IL-2 may be a treatment option for mesothelioma. A formal phase 
II study is warranted. Based on the observed toxicity, the lack of dose-response relationship and the 
immunomodulatory effects seen at relatively low-dose IL-2, the recommended dose for a phase II study is 
3 x  106 IU d ay-1 using the present treatment schedule.
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Untreated patients with pleural mesothelioma have a median 
survival of 9 months and may survive just as long as treated 
patients (Hillerdal, 1983; Law et a l 1984). Current treatment 
methods do not appear to improve survival (Alberts et al., 
1988). Therefore, new treatment modalities should be inves­
tigated.
In intraperitoneal tumour models it has been demonstrated 
that intracavitary administration of interleukin 2 (IL-2) can 
induce very high numbers o f lymphokine-activated killer cells 
(LAKs) in the peritoneal exudate (Eggermont et al., 
Eggermont 1989). Consequently, intrapleural administration 
of IL-2 for the treatment o f pleural mesothelioma appears to 
be a reasonable therapeutic approach, particularly since 
mesothelioma tends to be confined to the pleural cavity for 
most of the course of the disease. Yasumoto et al. (1987) 
reported the complete clearance of malignant cells after int­
rapleural instillations of IL-2 in patients with pleurisy due to 
lung cancer. Astoul et al. (1993) reported objective responses 
in mesothelioma patients treated with continuous intrapleural 
IL-2 instillation.
Based on these observations, we performed phase I—II 
study with intrapleural IL-2 in patients with pleural 
mesothelioma stage I—IIA, classified according to the But- 
chart staging system (Butchart et al., 1976).
Patients and methods
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Staging and diagnosis of mesothelioma was based on com­
puterised tomographic (CT) scan of the chest, thoracoscopic 
findings and histological examination of biopsy samples. 
All biopsies were reviewed by our institution’s pathologist.
included haematoxyiin and 
eosin, special stains for reticulin and mucins (such as
acid-Schiff after diastase and 
with and without prior digestion with 
hyaluronidase) and the immunohistochemistry stain for 
CEA, keratin, CAM-5.2 and an epithelial membrane antigen
MOC-31.
According to Butchart’s staging system (Butchart et al., 
1976) stage I is defined as tumour confined within the capsule 
of the parietal pleura, i.e. involving only ipsilateral pleura, 
lung, diaphragm and external surface of the pericardium 
within the pleural reflection. Stage I1A is 
mesothelioma invading chest wall or mediastinal tissues with 
or without lymph node involvement ipsilaterally inside the 
chest.
Eligibility criteria required histologically confirmed pleural 
mesothelioma stage I—IIA, sufficient pleural effusion to insert 
an intrapleural catheter, no signs of loculation on the CT 
scan, no prior chemo-, radio- or immunotherapy, age < 7 6  
years, Karnofsy performance status >  80, no cardiovascular 
disease, a white blood cell count >4000 ml-1, a platelet
as
count >  100 000 ml" , haematocrit >30% , serum bilirubin 
and creatinine levels within the institution’s normal range, no
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active infection, no use of corticosteroids and obtained in­
formed consent.
Treatment
One to two weeks before the first administration of IL-2 a 
Port-a-cath system was surgically inserted under general 
anaesthesia. The correct intrapleural position of the catheter 
was examined radiographically and a technetium-99m colloid 
scan was made to evaluate the distribution of pleural fluid 
throughout the pleural cavity.
Recombinant human IL-2 (Chiron, Amsterdam, The 
Netherlands) was administered as a continuous intrapleural 
infusion at a dose according to a groupwise dose escalation 
schedule (group A, 3 x 104; group B, 3 x 105; group C, 
3 x 106; group D, 6 x 106; group E, 18 x 106; and group F, 
36 x 106 IU day"1) for 14 days, repeated every 4 weeks. After 
two cycles, response to treatment was evaluated. Each group 
consisted of at least three patients. Patients with stable 
disease or response could receive up to a maximum of six 
cycles. No intra-patient dose escalation was performed.
All patients were seen weekly at the outpatient clinic. 
Masks and sterile gloves were used for all dressing changes 
and dressings were changed only by trained nursing person­
nel.
Response and toxicity
Response was evaluated after every two treatment cycles 
using CT scan of the chest. Tumour response and toxicity 
were assessed according to the criteria of the World Health 
Organization (1979). In case of measurable disease, complete 
response (CR) was defined as the disappearance of all known 
disease for at least 4 weeks; partial reponse (PR) as a 
decrease > 50%  in tumour size for at least 4 weeks; stable 
disease (SD) as a decrease o f <  50% in tumour size. Progres­
sive disease (PD) was defined as an increase > 25%  in the 
diameter of any lesion or the appearance of a new lesion.
In case of unmeasurable but evaluable disease a CR was 
defined as the complete disappearance of all known disease 
for at least 4 weeks; a PR as an estimated decrease in tumour 
size o f >  50% for at least 4 weeks; SD as an estimated 
decrease of less than 50% and lesions with estimated increase 
of less than 25%. PD was defined as the appearance of any 
new lesion not previously identified or estimated increase of 
25% or more in existent lesions.
Pleural effusion was not considered an adequate parameter 
o f response or progression by itself. It would not detract 
from a PR or SD. However, its continued presence would 
reduce a CR to a PR.
Time to progression and survival was calculated from the 
start o f treatment to the date o f progressive disease or death 
respectively, according to the Kaplan and Meier (1958) 
method.
Toxicity was recorded and analysed using the WHO 
grading system. For toxicities not included in the WHO 
guidelines, a grading system was used ranging from mild 
(grade 1) to life-threatening (grade 4).
Immunomonitoring
All samples were taken at the same time of day (preferably in 
the morning) since a circadian rhythm has been described for 
a number o f functions. Mononuclear cells (MNCs), serum 
samples and pleural fluid (if present) were collected weekly 
during each course and cryopreserved until tested.
I mm unophenotyp ing
MNCs were isolated from heparinised pleural and peripheral 
blood samples by density centrifugation (Ficoll-Isopaque). 
MNCs were washed, resuspended at a concentration of 
1 X 106 m l-1 in phosphate-buffered saline (PBS) +  1% bovine 
serum albumin (BSA) and stained with fluorescein
isothiocyanate (FITC)- or phycoerythrin (PE)-conjugated 
monoclonal antibodies (MAbs).
The following MAbs were used: anti-Leu4/FITC (CD3); 
anti-Leu3a/FITC (CD4); anti-Leu2a/PE (CD8); anti-Leu 1 lc/ 
PE (CD 16); anti-Leu 12/FITC (CD 19) and anti-Leu 19/PE 
(CD56). All MAbs were purchased from Becton and Dickin­
son, (San Jose, CA, USA).
After incubation with the MAb for 30 min at 0°C, MNCs 
were fixed in PBS containing 1% paraformaldehyde, stored 
at 4°C and flow cytometry was performed within 24 h using a 
FACScan (Becton and Dickinson).
Cytotoxicity assays
Cytotoxic activity of MNCs was determined in a standard 
3h  chromium-51 release assay. Briefly, lymphocytes were 
seeded in triplicate in 96-well, round-bottomed microtitre 
plates. Target cells labelled with chromium-51 were added 
and at the end of the incubation period (37°C and 5% 
carbon dioxide), supernatants were collected, and chromium- 
51 release was measured. Target cells were the NK-sensitive 
K562 chronic myelogenous leukaemia cell line and the NK- 
resistant, LAK-sensitive Daudi Burkitt lymphoma cell line.
Determination of cytokine levels
In patients from whom pleural fluid could easily be obtained, 
this was done before and during treatment with IL-2. At the 
same time blood samples were taken in order to compare 
intrapleural IL-2 and tumour necrosis factor alpha (TNF-a) 
levels with simultaneous blood IL-2 and TNF-a levels.
IL-2 was measured with a double antibody radio­
immunoassay using a polyclonal antiserum (IRE-Medgenix, 
Fleurus, Belgium). The detection limit is about 0.5 U ml-1 
(3.0 IU ml"1). The interassay coefficient of variation at a level 
of 104U m l"1 is 6.8%. One unit in this assay corresponds
with 6 IU.
TNF-a was measured with a coated tube 
immunoradiometric assay (IRE-Medgenix, Fleurus, Bel­
gium). The detection limit is 5 n g l _1 and the interassay 
coefficient of variation at a level of 131 ng 1~1 is 7.2%.
Results
Toxicity profile and tumour response
Twenty-three male patients with epithelial type malignant 
pleural mesothelioma stage I or IIA, without prior treatment, 
were eligible for the study. Most of them were shipyard 
workers with a history of asbestos exposure. Their median 
age was 57 (range 47-71) and their median Karnofsky per­
formance status 100 (range 90-100).
Twenty-one patients were evaluable for toxicity and 
tumour response (Tables I and II). Two patients were 
inevaluable for toxicity and response owing to catheter- 
related problems which prevented the delivery of any IL-2. 
At least one treatment cycle of 14 days was received by five 
patients at 3 x 104 IU day“ 1, two patients at 3 x l 0 5IU 
day-1, three patients at 3 x  106 IU day_1, three patients at 
6 x 10fi IU day-1, three patients at 18 X 106 IU day"1 and 
one patient at 36 X 106IU day-1. Five patients were started 
at the highest dose level but only one patient was able to 
receive one cycle. The other four patients were unable to 
complete one treatment cycle because o f catheter-related 
infections which required catheter removal before the com­
pletion of the first cycle! After five patient entries at this dose 
level the study was stopped. Hence, this dose was not 
tolerated by four of the five patients (Table I).
In general IL-2-mediated toxicity was mild to moderate, 
except at the highest dose level. At this level, in addition to 
the catheter-related infections, fever and flu-like symptoms 
were dose limiting. The systemic side-effects such as fever and 
skin toxicity corresponded with serum IL-2 levels, which 
reached 30IU m l-1 in group F. All patients received their
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Table I Toxicity in relation to intrapleural IL-2 in 21 evaluable patients (WHO grade >  2)
3 X 10* 3 X 10s
Dose level (IU) 
3 X K f  6 X 1& 18 x 1 0 s 36 X l ( f
Group A B C D E F
Patients 5 2 3 3 3 5
No. o f cycles 14 8 11 10 7 4
Fever > 38°C Ia 1 1 2 5
Flu-like — 1 1 — — 4
Myalgia 1 — 1 — 2
Arthralgia — 1 — 1 — M W *
Diarrhoea — . — — — 1
Non-productive cough 1 1 2 1 1 1
Dyspnoea 1 — I 2 2 —
Arrhythmia — 1 MM««
Anorexia — — — 1 1 1
Skin M M — — — 3
Creatinine elevation + n t m « N M « — 1
Leucocytosis (> 1 0  000 cells m l-1) I 1 1 3 3 3
Eosinophilia (> 2 0 0 0  cells ml"1) 1 2 2 1 1
Infection — 1 1 — 1 4
Bacterial culture S. aureus 5. aureus Streptococcus S. epidermidis (3)
Eubacterium ( 1 )
Thoracotomy due to empyema 1 2 * N M 1 1
“Number of patients per dose level experiencing toxicity
Table II Clinical data and response to therapy in 21 evaluable patients with pleural mesothelioma
treated with intrapleural IL-2
Patient
number
IL-2
(IU d a y -1) Age
No. o f  
cycles Response
Progression-free
survival
(months)
Overall
survival
(months)
1 3 x  104 51 4 PR 5 15
2 3 x  104 47 1 SD 4 8
3 3 x  104 50 0 NE“ i m M 7.5
4 3 x  104 63 5 SD 5 9
5 3 x  104 71 2 PD 1 5
6 3 x  104 57 2 PD 1 19
7 3 x  105 49 0 NE" 10
8 3 x  105 54 6 PR 17 23
9 3 X 10s 52 2 PD 1 10
10 3 X 106 59 1 PR 12 31
11 3 x 106 62 4 SD 3 6
12 3 x  106 51 6 PR 37 43
13 6 x  106 63 6 SD 5,5 28
14 6 x  106 64 2 PD 1 16
15 6 x  106 62 2 PD 1 17
16 18 X 106 69 2 SD 7 10
17 18 x  106 62 3 SD 2 18
18 18 x 106 59 2 PD 2 3
19 36 X 106 48 2 X i SD 6 10
20 36 X 10* 49 1 SD 9
21 36 x 106 55 1 SD 5 26
22 36 x 106 54 SD _b 16
23 36 x 106 59 3/4 SD 26 +
“Patients 3 and 7 did not receive ÏL-2 intrapleurally owing to catheter-related problems and were thus 
inevaluable. bPatients 20» 22 and 23 received additional cisplatin and etoposide, thus appropriate 
progression-free survival cannot be determined.
treatment in an outpatient setting except for the last five removal o f the Port-a-cath system in combination with
patients who were treated at level F, 36 x  106 IU day-1. No drainage by thoracotomy. As can be seen in Table I a variety
serious systemic adverse effects such as hypotension, car- of micro-organisms were cultured from pleural samples and
diovascular disturbances, pulmonary oedema, liver and renal removed Port-a-cath systems of these patients which suggests
dysfunction were observed, with the exception o f one patient a secondary bacterial infection in necrotic tissue.
Patients received from less than one up to six complete 
treatment cycles. There were no complete responses. Partial 
response occurred in 4 o f 21 evaluable patients (19%; 95% 
confidence intervals 5-42% ) with a median time to progres- 
Treatment-related complications were infection of the Port- sion of 12 months (range 5-37). Stable disease occurred in 
a-cath systems in seven patients, four of whom were treated seven patients, the median time to progression was 5 months
^___, , _ A _ M ild
leucocytosis (10 000-12  000 cells ml-1) and eosinophilia 
(2000-3500 cells ml-1) in the peripheral blood were seen in 
most patients at all dose levels.
at the highest dose level in group F. (range 2 -7 ). Six patients had progressive disease. The
Clinical signs of empyema were noted in five o f the seven median overall survival was 15.6 months (range 3.0-43).
patients with a Port-a-cath infection. These five required Responses occurred at different dose levels, therefore no
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dose-response relationship can be established (Table II). 
Figure 1 shows a representative example of a tumour res­
ponse.
Three of the four PRs was a long-lasting response under­
went thoracotomy. In patients 10 and 8, an infected Port-a- 
cath with concomitant empyema was noted after one and 
four cycles, respectively (Table II). In both these patients 
massive tumour necrosis was found. Bacterial cultures 
revealed Staphylococcus aureus in both cases. In patient 8, 
whose near-complete response lasted 17 months, a fenestra­
tion of the thoracic wall had to be performed in order to 
prevent recurrent empyema. In a second stage, the pleural 
cavity, which was macro scop ically still free of tumour, was 
closed by a pedicled omentoplasty. The patient did very well 
for 17 months, until mesothelioma developed in the cont­
ralateral pleural cavity. In patient 12, a fistula developed 
after five cycles and required ribresection. Thoracotomy 
showed a completely necrotised pleural mesothelioma. 
Bacterial cultures were negative. One of the multiple pleural 
biopsies contained mesothelioma cells. Two patients with SD, 
patients 19 and 16, showed clinical signs of empyema after 
one and two cycles respectively. A thoracotomy was per­
formed and extensive necrosis was found in the remaining 
tumour. Bacterial culture revealed Streptococcus in one and 
was negative in the other patient. In these three patients (12, 
16 and 19) CT scans showed no tumour regression whereas 
histological examination revealed extensive tumour necrosis. 
These findings underscore the difficulties in the clinical 
evaluation of response in mesothelioma.
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Immunomonitoring
After intrapleural administration of IL-2 a mild increase of 
CD3~56+, CD3+56+ and CD3"16+ lymphocytes was 
observed in pleural effusion as well as in peripheral blood. 
All other T-lymphocyte subsets remained at normal levels.
At dose levels A - D  cytotoxicity assays showed a 
significant induction of LAK activity by pleural effusion- 
derived MNCs but not by peripheral blood MNCs. At dose 
levels E and F, LAK activity was induced in MNCs from 
both sites. Of note, no differences in LAK activity were seen 
between responders and non-responders.
Determination of cytokine levels
Intrapleural as well as serum IL-2 levels were determined. 
Intrapleural levels were very high and correlated with the 
administered dose of IL-2. Intrapleural levels varied from 
110 IU ml-1 in group A to as high as 66 000-192 000 IU 
in group F. Serum IL-2 levels became measurable only 
in groups E and F and varied in the eight patients treated at 
those levels from < 3 I U m l _1 to 30IUml~' .  Intrapleural 
IL-2 levels were < 6000  times higher than serum levels.
1 in
6 “
ml
Intrapleural TNF-a levels varied from 50-125 pg ml-1
group A to 235-405 pg ml-1 in group F. However, no clear 
relationship between TNF-a and IL-2 levels was observed as 
TNF-a levels in groups B -E  varied from 292-1141 pgm l-1.
b
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Figure 1 Partial reponse of pleural mesothelioma (evaluable 
disease) and a mediastinal lymph node (measurable disease) 
metastasis in the left hemithorax. (a) Pretreatment CT scan, (b)
After two cycles of IL-2.
In this phase I-II  study on the toxicity and efficacy of 
intrapleural administration o f IL-2 in patients with pleural 
mesothelioma we observed anti-tumour activity with accep­
table toxicity. The response rate of 19% in 21 patients is o f  
interest as mesothelioma is known to be refractory to treat­
ment.
The basis of this study was the observation of a 
dose-response relationship in experimental tumour models 
(Ettinghausen et al., 1986; Rosenberg et a i,  1987, 1989;
Eggermont et al., 1988). Systemic high-dose IL-2 therapy is 
associated with severe toxicity, which may prohibit applica­
tion of doses with optimal anti-tumour effects (Herberman,
1989). Intrapleural administration of IL-2 is therefore a with 36 x 106 IU day-1. All patients in groups A -E  were
levels of IL-2 can be delivered without severe systemic 
adverse effects. We have demonstrated that high intrapleural 
levels of IL-2 are associated with mild to moderate toxicity, 
except in those patients treated at the highest dose level F
1
logical approach as it can be expected that very high local treated on an outpatient basis.
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Intrapleural administration of various biological response 
modifiers may have significant anti-tumour effects against 
intrapleural malignant disease. Uchida et al. (1984) reported 
that intrapleural instillation with the biological response 
modifier OK-432 significantly increased autologous tumour 
killing by tumour-associated large granular lymphocytes. The 
intrapleural instillation of natural j3-interferon was reported 
to be effective against malignant pleural effusions by Rosso et 
al. (1988). Recently, Markowitz et al. (1992) reported on the 
efficacy of intracavity administration of a-interferon. Boutin 
et al. (1991) reported four CRs and two PRs after weekly 
intrapleural administration o f 7-interferon in 22 patients with
Immunophenotyping o f intrapleural and peripheral MNCs 
showed some changes after intrapleural administration of 
IL-2. In this study, the dose of IL-2 did not correlate with 
response and none of the parameters investigated by 
immunophenotyping, cytotoxicity assays and determination 
of cytokine levels corresponded with the outcome of treat­
ment.
Dosages of IL-2 in this study were tolerable up to and 
including level E, 18 X 106 IUday-1. However, at level F, 
36 x 106 IU day-1, catheter-related infection was the most 
pronounced and dose-limiting side-effect. Others have 
reported neutrophil dysfunction during IL-2 administration,
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mesothelioma, also underlining the therapeutic potential of including decreased chemotaxis and Fc receptor expression
loco regional cytokine therapy.
Anti-tumour effects after intrapleural administration of 
TNF-a have been reported by Karck et al. (1990). Int­
rapleural administration < 2 0 0  fig m ~2 weekly in seven 
patients with malignant pleural effusion led to complete 
disappearance of tumour in three patients without side- 
effects. The same group reported that in patients with 
ovarian cancer and recurrent ascites intraperitoneal administ­
ration of TNF-a resulted in the disappearance of ascites in 
seven of nine patients.
Yasumoto et al. (1987) demonstrated that low intrapleural 
doses of IL-2 were sufficient to induce LAK activity in the 
pleural exudate and to reduce malignant pleural effusions. 
Manning et al. (1989) have shown that these activated lym­
phocytes were able to kill NK cell-resistant human 
mesothelioma cells.
Astoul et al. (1993) reported a relatively high response rate 
(7/15 patients) in mesothelioma patients who were treated 
with intrapleural IL-2 in a dose escalation study. The 
preponderance of responses was observed in stage I disease.
We made similar observations in our study. Significant
LAK activity was displayed by MNCs collected from the 
pleural effusions after intrapleural administration of IL-2. No 
LAK activity was displayed by the peripheral MNCs, except 
at the highest two dose levels in groups E and F. However,
(Murphy et al., 1988; Jablons et al., 1990; Klempner et al., 
1990). High-dose IL-2 increased the risk of bacteraemia 
significantly, which led to a reduction of catheter indwelling 
time (Richards et al., 1991). These facts may explain the high 
incidence o f catheter-related infections in our patients, partic­
ularly in group F, and after repeated administration of IL-2 
at the lower doses.
It remains uncertain if and to what extent these infections 
have played a role in the induction of an anti-tumour res­
ponse, as three of the four responders developed an 
empyema, but two of the five patients with an empyema had 
no response. In addition, IL-2 by itself induced high int­
rapleural levels of TNF-a in the majority of the patients 
treated.
We conclude that intrapleural administration of cytokines 
should be explored further as a new mode of treatment for 
pleural mesothelioma. IL-2 given intrapleurally appears to 
have anti-tumour activity against mesothelioma. We are 
aware of the difficulty in recommending a daily dose of IL-2 
because of the small numbers of patients in each group and 
the frequent occurrence of empyema, but given the facts that 
( 1) no correlation was found by us and by others between 
IL-2 dose and anti-tumour response, (2) low intrapleural IL-2 
doses are sufficient to induce LAK activity by MNCs which 
can kill NK cell-resistant human mesothelioma cells and (3) 
LAK activity and response did not correspond with IL-2 mild toxicity was seen below 6 x 106 IU of IL-2 we suggest a 
dose level, intrapleural IL-2 level or intrapleural TNF-a level. daily dose of 3 x 106 IU of IL-2 for a phase II study.
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